A decision is not expected to be imminent, one source said, but debate within the administration has shifted recently to more deeply exploring how and when the act might be invoked.

U.S. Secretary of State Marco Rubio has repeatedly said “no one has died" because of his government’s decision to gut its foreign aid program.

Gilead’s Lenacapavir Tablet and Injection Products Prequalified by WHO

A gene therapy method using AAV can help deliver HIV-fighting antibodies long-term, but the body often rejects them. Here the authors show that a short course of the drug rapamycin helps prevent host anti-drug antibody responses, showing successful antibody delivery in mice and monkeys.

MSF warns global health funding cuts risk reversing progress against HIV, TB and malaria. Critical action is needed to sustain critical programs worldwide.

Join us Thursday, October 23 at 12:00 pm ET, as we explore the profound impact language has on the wellness and overall health of women living with HIV.

People living with HIV with history of cured pulmonary TB have circulating immune cells with differential gene expression enriched in TNF-related pathways,

During infection, HIV-1 establishes a rebound-competent viral reservoir (RCVR), a pool of long-lived sources of replication competent virus that can persist in the face of suppressive combination antiretroviral therapy (cART) for the lifetime of an individual with HIV (1–7). Most of the RCVR is composed of cells harboring transcriptionally silent, or latent, viral genomes (8–11), but in response to various triggers, a level of cellular activation leading to virus expression, up to and including the production of infectious virions may occur. Combination ART does not prevent this process, but rather it inhibits the de novo spread of infection to previously uninfected cells, thereby preventing progressive infection. However, if cART is interrupted, virus produced from one or more of these reactivating viral genomes can spread, leading to recrudescent systemic infection characterized by rebound plasma viral loads (PVL) (12–14) and, should cART not be resumed, eventual progression to AIDS. While the precise timing of RCVR formation has been the subject of debate, current data suggest that it forms early following initial infection and likely evolves over the course of untreated infection (15–19). Thus, due to the early establishment and longevity of the RCVR, lifelong cART initiated at first HIV diagnosis is now indicated for virtually all people with HIV (PWH). However, concerns about the costs, accessibility, lifelong compliance, and potential emergence of drug-resistant viral mutants make lifelong cART for the nearly 40 million PWH worldwide a daunting challenge. Additionally, PWH on cART still have an elevated risk of non-AIDS morbidities and mortality associated with persistently elevated immune activation and inflammation that may be due, in part, to the persistent presence of virally infected cells (20–24). Accordingly, there is a global research effort to identify more definitive treatment for HIV-1, be it true viral clearance or durable viral remission, that would allow for cART to be safely discontinued.